Pancreatic Cancer in 2014

  • Serafim Kaltsas University of Athens School of Medicine. Athens Greece
  • Konstantinos N Syrigos University of Athens School of Medicine. Athens Greece
  • Muhammad Wasif Saif Tufts Medical Center. Boston, MA, USA
DOI: https://doi.org/10.6092/1590-8577/2403
Keywords: Carcinoma, Pancreas, Pancreatic Neoplasms, Therapeutics /toxicity

Abstract

No abstract available.

Image: Purple Crane (Folded by school children for pancreatic cancer patients).
From Wikimedia Commons (Author: Erinleary). http://commons.wikimedia.org/wiki/File:Purple_Crane.jpg

Downloads

Download data is not yet available.

Author Biography

Muhammad Wasif Saif, Tufts Medical Center. Boston, MA, USA

Wasif Saif, MD

Director, Gastrointestinal Oncology Program

Leader, Experimental Therapeutics Program

References

American Cancer Society. Cancer Facts & Figures 2013. Atlanta, Ga: American Cancer Society; 2013.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25.

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 16.

Saif MW. Advancements in the management of pancreatic cancer: 2013. JOP. J Pancreas (Online) 2013; 14:112-8.

Sangar V, Ricigliano M, O'Reilly EM, Abou-Alfa GK, Lowery MA, Saltz L,et al. Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance. J Clin Oncol 30: 2012 (Suppl 34): Abstract 142.

Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6.

Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, et al. A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. J Clin Oncol 2013; 31(Suppl): Abstract 4010.

Fong PC, Boss DS, Yap TA, Tutt A, Wu PJ, Mergui-Roelvink M, et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. N Eng J Med 2009; 361:123-34.

Leung K, Saif MW. BRCA-associated pancreatic cancer: the evolving management. JOP. J Pancreas (Online) 2013; 14:149-51.

Study of MM-398 with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer (NAPOLI 1). NCT01494506, ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT01494506

Incyte’s shares rise on positive mid-stage survival data for Jakafi in pancreatic cancer. FirstWord Pharma. http://www.firstwordpharma.com/node/1133046?tsid=17#axzz2sayzAB5H

Glufosfamide versus 5-FU in second line metastatic pancreatic cancer. NCT01954992, ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01954992

Purple Crane.jpg (Folded by school children for pancreatic cancer patients). [Author: Erinleary. From Wikimedia Commons]
Published
2014-03-10
How to Cite
KaltsasS., SyrigosK., & SaifM. (2014). Pancreatic Cancer in 2014. JOP. Journal of the Pancreas, 15(2), 84-86. https://doi.org/10.6092/1590-8577/2403
Issue
Vol 15 No 2 (2014): March - p. 84-218
Section
EDITORIALS

Copyright (c) 2014 Serafim Kaltsas, Konstantinos N Syrigos, Muhammad Wasif Saif

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.

Most read articles by the same author(s)

1 2 > >>